Huhn Stephen L. 4
4 · Contineum Therapeutics, Inc. · Filed Aug 14, 2024
Insider Transaction Report
Form 4
Huhn Stephen L.
CMO & Sr VP, Clinical Dev.
Transactions
- Exercise/Conversion
Class A Common Stock
2024-08-13$1.01/sh+12,800$12,928→ 12,800 total - Exercise/Conversion
Stock Option (right to buy)
2024-08-13−12,800→ 161,394 totalExercise: $1.01Exp: 2030-02-24→ Class A Common Stock (12,800 underlying)
Footnotes (2)
- [F1]This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of Class A Common Stock.
- [F2]Options granted under the Issuer's 2012 Equity Incentive Plan. The option is fully vested.